Ben Sasse was given a few months to live. He credits "providence, prayer and a miracle drug" for giving him more time. [CBS News]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: CBS News
He credits "providence, prayer and a miracle drug" — a clinical trial that has shrunk his tumors by 76% — for buying him more time. Patients who typically would have had about six months to live are living around 13 months with Revolution Medicines' daraxonrasib. Sasse talked at length about his diagnosis, his family and his faith in an interview with Scott Pelley, airing Sunday on "60 Minutes." You can watch even more of their conversation in a special edition of "Things That Matter," which will be available Sunday night on Paramount+ CBSNews.com , and YouTube The former senator also had plenty to say about the state of American politics, and Congress in particular. "Neither of these parties really have very big or good ideas about 2030 or 2050," he said. "The Congress is not wrestling with bigger important questions right now."
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines (RVMD) had its price target raised by Leerink Partners from $147.00 to $171.00. They now have an "outperform" rating on the stock.MarketBeat
- Revolution Medicines (RVMD) had its "buy" rating reaffirmed by HC Wainwright. They now have a $169.00 price target on the stock.MarketBeat
- Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual MeetingGlobeNewswire
- Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual MeetingGlobeNewswire
- Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual MeetingGlobeNewswire
RVMD
Earnings
- 2/25/26 - Miss
RVMD
Sec Filings
- 4/17/26 - Form 4
- 4/17/26 - Form 8-K
- 4/16/26 - Form 8-K
- RVMD's page on the SEC website